公开(公告)号：US10202376B2

公开(公告)日：2019-02-12

申请号：US15538297

申请日：2015-12-21

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Eiji Kimura ,  Yuhei Miyanohana ,  Masaki Ogino ,  Yuta Tanaka ,  Makoto Fushimi ,  Tomohiro Okawa ,  Yuki Hanya ,  Tatsuki Koike

IPC: C07D471/04 ,  A61K31/437 ,  C07D487/04 ,  A61P25/00 ,  A61P29/00

Abstract: Provided is a compound having an antagonistic action on an NMDA receptor containing the NR2B subunit, and is useful as a prophylactic or therapeutic agent for major depression, bipolar disorder, migraine, pain, peripheral symptoms of dementia and the like. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, (excluding N-(4-bromo-3-(1H-1,2,4-triazol-5-yl)thiophen-2-yl)-2-(imidazo[1,2-a]pyridin-5-yl)acetamide) or a salt thereof.

公开(公告)号：US09963443B2

公开(公告)日：2018-05-08

申请号：US15316937

申请日：2015-06-08

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Tatsuki Koike ,  Shuhei Ikeda

IPC: A61K31/506 ,  C07D401/14 ,  A61K51/04 ,  C07D401/04 ,  C07D405/14 ,  C07D417/14

CPC classification number: C07D401/14 ,  A61K51/0455 ,  A61K51/0459 ,  C07B59/002 ,  C07B2200/05 ,  C07D401/04 ,  C07D405/14 ,  C07D417/14

Abstract: The present invention provides radiolabeled compounds useful as radiotracers for quantitative imaging of CH24H in mammals. The compound of the present invention is represented by the formula (I): wherein each symbol is as defined in the specification.

公开(公告)号：US11495331B2

公开(公告)日：2022-11-08

申请号：US16766559

申请日：2018-09-10

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED ,  PATCORE, INC.

Inventor： Hiroshi Nara ,  Junya Shirai ,  Tatsuki Koike ,  Kenjiro Sato ,  Takaharu Hirayama ,  Hiromi Fukuda ,  Tsutomu Morita ,  Hiromasa Ishihara ,  Kazue Suzuki ,  Hiroki Sakamoto ,  Fumiaki Kikuchi ,  Kenta Tamaki ,  Toru Tanoue ,  Yuichi Horita ,  Takeshi Ueda

IPC: G16H15/00 ,  G16C20/80 ,  G16C20/10

Abstract: An objective of the present invention is to provide a document creation assistance server and document creation assistance method which are capable of efficiently acquiring information necessary to write a specification or other such documents, and of generating a document from the acquired information. According to an embodiment, this document creation assistance server for assisting with the creation of a document comprises: a final product identification part for accepting identification information for identifying a final product generated by synthesizing a plurality of chemical compounds; a chemical equation acquisition part for referring to electronic experiment note data which provides an electronic record of the details of an experiment relating to the synthesis of the chemical compounds, and acquiring a chemical equation for generating the final product associated with the accepted identification information; and a document generation part for generating a document including the acquired chemical equation.

公开(公告)号：US20200247747A1

公开(公告)日：2020-08-06

申请号：US16777273

申请日：2020-01-30

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Yasushi Hattori ,  Yuhei Miyanohana ,  Yuichi Kajita ,  Tatsuki Koike ,  Yasutaka Hoashi ,  Norihito Tokunaga ,  Alexander Martin Pawliczek ,  Tsuneo Oda ,  Tohru Miyazaki ,  Yoshiteru Ito ,  Kohei Takeuchi ,  Keisuke Imamura ,  Takahiro Sugimoto

IPC: C07D207/14 ,  C07D417/06 ,  C07D407/08

Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity.A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.

公开(公告)号：US10548877B2

公开(公告)日：2020-02-04

申请号：US16083295

申请日：2017-03-09

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Masaki Ogino ,  Eiji Kimura ,  Shinkichi Suzuki ,  Kouji Fuji ,  Tomohiro Ohashi ,  Makoto Fushimi ,  Kei Masuda ,  Tatsuki Koike ,  Takeshi Wakabayashi ,  Jinichi Yonemori ,  Masami Yamada

IPC: A61K31/4192 ,  A61K31/415 ,  A61K31/4155 ,  A61K31/427 ,  A61K31/4406 ,  A61K31/4439 ,  A61P25/20 ,  A61P25/28 ,  A61P25/18 ,  A61P25/16 ,  C07D213/56 ,  C07D231/12 ,  C07D249/06 ,  C07D401/04 ,  C07D405/12 ,  C07D405/14 ,  C07D413/12 ,  C07D417/12

Abstract: Provided is a compound having a cholinergic muscarine M1 receptor positive allosteric modulator activity. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof has a cholinergic muscarine M1 receptor positive allosteric modulator activity, and is useful as a prophylactic or therapeutic drug for Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies and the like.

公开(公告)号：US10428023B2

公开(公告)日：2019-10-01

申请号：US16052967

申请日：2018-08-02

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Yuichi Kajita ,  Yuhei Miyanohana ,  Tatsuki Koike ,  Kohei Takeuchi ,  Yoshiteru Ito ,  Norihito Tokunaga ,  Takahiro Sugimoto ,  Tohru Miyazaki ,  Tsuneo Oda ,  Yasutaka Hoashi ,  Yasushi Hattori ,  Keisuke Imamura

IPC: C07D211/56 ,  A61P25/00 ,  C07D205/04 ,  C07D207/14 ,  C07D401/06 ,  C07D401/10 ,  C07D401/14 ,  C07D403/06 ,  C07D405/10 ,  C07D405/12 ,  C07D413/06 ,  C07D417/06 ,  C07D417/14 ,  C07D405/06 ,  C07D211/36

Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity.A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof, is useful as an agent for the prophylaxis or treatment of narcolepsy.

公开(公告)号：US10144743B2

公开(公告)日：2018-12-04

申请号：US15424075

申请日：2017-02-03

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Tatsuki Koike ,  Masato Yoshikawa ,  Haruhi Ando ,  William John Farnaby

IPC: C07D498/08 ,  C07D401/14 ,  C07D405/14 ,  C07D413/14 ,  C07D401/10 ,  C07D413/10 ,  C07D417/14 ,  C07D405/10

Abstract: The present invention provides a compound useful as an agent for the prophylaxis or treatment of neurodegenerative disease and the like, or a salt thereof.The present invention relates to a compound represented by the formula wherein each symbol is as defined in the specification, or a salt thereof.

公开(公告)号：US10106556B2

公开(公告)日：2018-10-23

申请号：US15563161

申请日：2016-03-29

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Shuhei Ikeda ,  Tatsuki Koike ,  Jumpei Aida ,  Makoto Fushimi ,  Tomokazu Kusumoto ,  Hideyuki Sugiyama ,  Masako Miyazaki ,  Hidekazu Tokuhara ,  Yasushi Hattori ,  Makoto Kamata

IPC: C07D498/04 ,  C07D413/14 ,  C07D401/06 ,  C07D413/06 ,  C07D417/14 ,  C07D471/04 ,  C07D401/10 ,  C07D413/10 ,  C12N9/99 ,  A61K31/454 ,  A61K31/4709 ,  A61K31/538 ,  A61K31/5383

Abstract: The present invention provides a compound having an MAGL inhibitory action, which is expected to be useful as an agent for the prophylaxis or treatment of neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, traumatic brain injury, glaucoma, multiple sclerosis etc.), anxiety disorder, pains (e.g., inflammatory pain, cancerous pain, neurogenic pain etc.), epilepsy, depression and the like.The present invention relates a compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof.

公开(公告)号：US09440990B2

公开(公告)日：2016-09-13

申请号：US14847703

申请日：2015-09-08

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Tatsuki Koike ,  Masato Yoshikawa ,  Haruhi Ando ,  William John Farnaby ,  Toshiya Nishi

IPC: C07D498/08 ,  C07D401/14 ,  C07D405/14 ,  C07D413/14 ,  C07D401/10 ,  C07D413/10 ,  C07D417/14

CPC classification number: C07D498/08 ,  C07D401/10 ,  C07D401/14 ,  C07D405/10 ,  C07D405/14 ,  C07D413/10 ,  C07D413/14 ,  C07D417/14

Abstract: The present invention provides a compound useful as an agent for the prophylaxis or treatment of neurodegenerative disease and the like, or a salt thereof. The present invention relates to a compound represented by the formula (I) wherein each symbol is as defined in the specification, or a salt thereof.

公开(公告)号：US20140228373A1

公开(公告)日：2014-08-14

申请号：US14349201

申请日：2012-10-03

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Tatsuki Koike ,  Masato Yoshikawa ,  Haruhi Ando ,  William John Farnaby

IPC: C07D417/14 ,  C07D413/10 ,  C07D401/14 ,  C07D405/14 ,  C07D401/10 ,  C07D413/14

CPC classification number: C07D498/08 ,  C07D401/10 ,  C07D401/14 ,  C07D405/10 ,  C07D405/14 ,  C07D413/10 ,  C07D413/14 ,  C07D417/14

Abstract: The present invention provides a compound useful as an agent for the prophylaxis or treatment of neurodegenerative disease and the like, or a salt thereof. The present invention relates to a compound represented by the formula (I) wherein each symbol is as defined in the specification, or a salt thereof.

Abstract translation: 本发明提供可用作预防或治疗神经变性疾病等的药剂或其盐。 本发明涉及由式（I）表示的化合物，其中每个符号如说明书中所定义，或其盐。